TLDRRoche stock rises 1.18% as third-quarter sales climb 7% at constant exchange rates.Roche reports CHF 46.5 billion in nine-month sales, fueled by key medicines.FDA approvals for Tecentriq and Enspryng expand Roche’s treatment portfolio.Roche’s top five medicines generate CHF 16.8 billion, up 12% at constant rates.Roche maintains its 2026 growth outlook amid drug approvals and diagnostics gains.Roche Holding AG (RHHBY) stock climbed 1.18% to $59.81, gaining $0.70 as strong third-quarter sales supported positive market momentum. The Swiss pharmaceutical company reported 7% quarterly sales growth at constant exchange rates, alongside several major FDA approvals. Meanwhile, growing demand for key medicines and progress across its drug pipeline strengthened its business performance.Roche Holding AG, RHHBYRoche Reports Strong Pharmaceutical Sales GrowthRoche generated CHF 46.5 billion in group sales during the first nine months of 2026, representing 6% constant-currency growth. The stronger Swiss franc reduced reported growth to 1%, despite continued demand for medicines and diagnostic products. Third-quarter revenue increased 8% in Swiss francs as currency pressures eased during the period.The Pharmaceuticals Division recorded CHF 36.2 billion in sales, reflecting 7% growth at constant exchange rates. Meanwhile, Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo generated combined revenue of CHF 16.8 billion. These five medicines delivered 12% constant-currency growth, supporting Roche’s performance across several major disease categories.Regional results also highlighted differences in pharmaceutical demand across Roche’s markets. Japan recorded 25% constant-currency growth, while international markets expanded 10% and the United States grew 5%. However, older medicines faced biosimilar competition, which reduced sales from several established treatments.Major FDA Approvals Strengthen Roche’s Drug PipelineRoche secured several US regulatory approvals during the quarter, expanding treatment options across cancer and autoimmune diseases. The FDA approved Tecentriq with chemotherapy for certain patients with stage III colon cancer following surgery. Clinical trial results showed the combination reduced disease recurrence or death risk by 50% compared with chemotherapy alone.The FDA approved Enspryng for thyroid eye disease, providing an at-home treatment option for eligible patients. Roche also secured Priority Review for fenebrutinib across relapsing and primary progressive multiple sclerosis. Phase III trials showed fenebrutinib reduced relapse rates by 51% and 58% against teriflunomide.Beyond regulatory progress, Roche reported positive clinical results across kidney disease, cancer, diabetes, and obesity programs. Its experimental diabetes treatment, enicepatide, achieved average weight loss of 15.5% at the highest dose after 48 weeks. Furthermore, Roche continues expanding its development pipeline and targets up to 20 new medicines by 2030.Diagnostics Growth and 2026 Outlook Support Business ExpansionRoche’s Diagnostics Division generated CHF 10.3 billion in nine-month sales, representing 4% constant-currency growth. Strong demand for laboratory and pathology products helped offset pricing reforms affecting diagnostic sales in China. North America delivered 9% growth, while Latin America expanded 12% at constant exchange rates.The FDA also cleared Roche’s Elecsys pTau217 blood test to support Alzheimer’s disease assessment. The test helps clinicians identify amyloid pathology through a single biomarker across primary and specialist care settings. Roche plans to use its existing US laboratory equipment network to support wider access.Roche maintained its full-year 2026 outlook following its third-quarter performance and regulatory progress. The company expects mid-single-digit group sales growth and high-single-digit core earnings-per-share growth at constant exchange rates. Roche expects another dividend increase in Swiss francs while expanding manufacturing and research operations in the United States. The post Roche Holding AG (RHHBY) Stock: Rises After Strong Q3 Sales and Major FDA Approvals appeared first on Blockonomi.